Brown JR et al. Pooled analysis of cardiovascular events from clinical trials evaluating acalabrutinib monotherapy in patients with chronic lymphocytic leukemia (CLL). ASH 2020;Abstract 3146.
Burger JA et al. Outcomes of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and high-risk genomic features with up to 6.5 years follow-up: Integrated analysis of two phase 3 studies (RESONATE-2 and iLLUMINATE). ASH 2020;Abstract 2220.
Crombie JL et al. Updated results from a phase I/II study of duvelisib and venetoclax in patients with relapsed or refractory CLL/SLL or Richter’s Syndrome. ASH 2020;Abstract 3141.
Davids MS et al. Updated safety and efficacy results from a phase 2 study of acalabrutinib, venetoclax and obinutuzumab (AVO) for frontline treatment of chronic lymphocytic leukemia (CLL). ASH 2020;Abstract 2216.
Ghia P et al. Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in relapsed/refractory chronic lymphocytic leukemia: Ascend final results. ASH 2020;Abstract 3140.
Gribben JG et al. Umbralisib plus ublituximab (U2) is superior to obinutuzumab plus chlorambucil (O + Chl) in patients with treatment naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Results from the phase 3 Unity-CLL study. ASH 2020;Abstract 543.
Harrup R et al. Efficacy of subsequent novel targeted therapies, including repeated venetoclax-rituximab (VenR), in patients (pts) with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) previously treated with fixed-duration VenR in the Murano study. ASH 2020;Abstract 3139.
Kater AP et al. Five-year analysis of Murano study demonstrates enduring undetectable minimal residual disease (uMRD) in a subset of relapsed/refractory chronic lymphocytic leukemia (R/R CLL) patients (pts) following fixed-duration venetoclax-rituximab (VenR) therapy (Tx). ASH 2020;Abstract 125.
Mato AR et al. LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Results from the phase 1/2 BRUIN study. ASH 2020;Abstract 542.
Munir T et al. Continued long term responses to ibrutinib + venetoclax treatment for relapsed/refractory CLL in the Blood Cancer UK TAP Clarity trial. ASH 2020;Abstract 124.
Siddiqi T et al. Updated follow-up of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma treated with lisocabtagene maraleucel in the phase 1 monotherapy cohort of Transcend CLL 004, including high-risk and ibrutinib-treated patients. ASH 2020;Abstract 546.
Thompson MC et al. Venetoclax re-treatment of chronic lymphocytic leukemia (CLL) patients after a previous venetoclax-based regimen. ASH 2020;Abstract 3136.
Wierda WG et al. Ibrutinib (ibr) plus venetoclax (ven) for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 1-year disease-free survival (DFS) results from the MRD cohort of the phase 2 CAPTIVATE study. ASH 2020;Abstract 123.
Wierda WG et al. Transcend CLL 004: Phase 1 cohort of lisocabtagene maraleucel (liso-cel) in combination with ibrutinib for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). ASH 2020;Abstract 544.
Woyach JA et al. Acalabrutinib in combination with venetoclax and obinutuzumab or rituximab in patients with treatment-naïve or relapsed/refractory chronic lymphocytic leukemia. ASH 2020;Abstract 1312.